Date | Price Target | Rating | Analyst |
---|---|---|---|
9/4/2024 | $31.00 | Equal-Weight | Morgan Stanley |
8/20/2024 | Overweight → Neutral | JP Morgan | |
7/15/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
2/23/2024 | $46.00 → $48.00 | Market Perform → Outperform | BMO Capital Markets |
1/22/2024 | Neutral → Sell | Citigroup | |
12/6/2023 | Neutral → Buy | UBS | |
11/10/2023 | Hold → Buy | Deutsche Bank | |
11/8/2023 | Sell → Buy | DNB Markets |
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m2 in patients with advanced ovarian cancer Genmab A/S (NASDAQ:GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 wee
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy Genmab A/S (NASDAQ:GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for
Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (NASDAQ:GMAB) today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated biotech innovation powerhouse. Genmab's Executive Committee will include Rayne Waller in the newly created role of Executive Vice President and Chief Technology Officer and Brad Bailey in the newly created role of Executive Vice President and Chief Commercial Officer. Execu
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumors Genmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark and SEATTLE, Washington; April 3, 2024 – Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for 2024. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investors. Conference CallGenmab will hold a conference call in English to discuss the full year results for 2023 today, February 14, 2024 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G - GENMAB A/S (0001434265) (Subject)
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
Morgan Stanley resumed coverage of Genmab with a rating of Equal-Weight and set a new price target of $31.00
JP Morgan downgraded Genmab from Overweight to Neutral
RBC Capital Mkts upgraded Genmab from Sector Perform to Outperform
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
During the last three months, 8 analysts shared their evaluations of Genmab (NASDAQ:GMAB), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 0 0 0 0 Last 30D 0 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 2 0 0 0 0 Analysts have set 12-month price targets for Genmab, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This upward trend is apparent, with the current average reflecting a 1.01% incre
RBC Capital analyst Alistair Campbell upgrades Genmab (NASDAQ:GMAB) from Sector Perform to Outperform.
Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera